Welcome to our dedicated page for Applied Optics news (Ticker: APOP), a resource for investors and traders seeking the latest updates and insights on Applied Optics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Applied Optics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Applied Optics's position in the market.
Cellect Biotechnology Ltd. (NASDAQ: APOP) announced a collaborative development program with XNK Therapeutics, focusing on enhancing NK cell-based therapies. This partnership aims to improve cancer targeting through Cellect's functional cell selection technology. CEO Dr. Shai Yarkoni emphasized the operational momentum and strategic vision driving potential revenue opportunities. The collaboration, part of a prestigious network including the Karolinska Institute, seeks to enhance manufacturing efficiency in stem cell applications. Cellect's technology supports advancements in regenerative medicine for cancer treatment.
Cellect Biotechnology Ltd. (NASDAQ: APOP) has launched a U.S. clinical trial for its ApoGraft technology aimed at improving bone marrow transplantation. This pivotal trial will enroll 18 patients and assess safety and tolerability over 180 and 360 days. Following a successful initial trial in Israel, the company aims to gather more data and publish results in early 2021. The trial is being conducted at Washington University School of Medicine, with a focus on preventing graft-versus-host disease (GVHD). This marks a significant advancement in Cellect's development journey.
Cellect Biotechnology Ltd. (NASDAQ: APOP) announced its upcoming presentation at the Cell & Gene Meeting on the Mesa from October 12-16, 2020. The company will discuss advancements in Bone Marrow Transplant (BMT) and Chimeric Antigen Receptor T Cell (CAR T) collaborations. Management emphasizes their commitment to enhancing cell and gene therapies despite the pandemic. They aim to meet with industry partners and share progress on clinical trials, particularly in CAR T, NK, and MSC therapies, while pursuing new revenue opportunities.
Cellect Biotechnology Ltd. (NASDAQ: APOP) reported its financial results for Q2 2020, highlighting ongoing challenges from COVID-19. Despite delays, the company is pursuing strategic initiatives in pain management and COVID-19 therapeutics. Financially, R&D expenses decreased to $0.39 million, and G&A expenses fell to $0.61 million. However, finance expenses rose to $1.54 million, resulting in a net loss of $2.54 million, or $0.007 per share. Cash and equivalents were $7 million as of June 30, 2020. The company aims to resume clinical trials and leverage its technology for long-term growth.
Cellect Biotechnology Ltd. (NASDAQ: APOP) announced the granting of European Patent Application No. 14851547.1, strengthening its intellectual property (IP) portfolio. This patent, expiring in October 2034, ensures IP protection for the activation of stem and progenitor cells, enhancing safety and efficacy in regenerative therapies. The company now holds 65 patents across nine families, with 45 granted. Cellect aims to leverage this achievement to boost business development and revenue, maintaining discussions with global cell therapy leaders.
Cellect Biotechnology Ltd. (NASDAQ: APOP) reported its Q1 2020 financial results, featuring a net loss of $0.72 million, down from $1.70 million in Q4 2019. Total cash amounted to $7.08 million. R&D expenses decreased to $0.43 million, while G&A expenses rose to $0.73 million due to 2019 bonus provisions. The company entered an international consortium to study stem cell therapies for COVID-19 and is negotiating a merger with Canndoc Ltd, although delays persist due to the pandemic. The company has strengthened its IP portfolio, holding 64 patents across multiple regions.
Cellect Biotechnology Ltd. (NASDAQ: APOP) announced that several investors agreed to exercise warrants to purchase 534,160,000 ordinary shares at a reduced exercise price of $2.75 per share, down from $7.50. The exercise is expected to yield approximately $1.5 million in gross proceeds, intended for working capital and other general corporate needs. The shares are registered under an SEC effective registration statement. Cellect's technology focuses on stem cell selection, supporting various regenerative medicine applications, including ongoing clinical trials for cancer treatment.